reports
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2...
Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury FREMONT, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided top-line 12 month data from the Company’s Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord i...
Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Hu...
Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer Two Sites in the UK Currently Enrolling Patients FREMONT, Calif., Nov. 27, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced enrollment and dosing of the fourth subject in the first-in-human Phase 1 clinical trial of VAC2 in th...
Asterias Biotherapeutics Reports Third Quarter Results
Asterias Biotherapeutics Reports Third Quarter Results Clinical Programs Continue to ProgressRecent Transactions with affiliate of Novo Nordisk Increased Cash-on-Hand and Reduced Annual Operating ExpensesRecently Announced Definitive Merger Agreement with BioTime Creates Leading Cell Therapy Company FREMONT, Calif., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today re...
Asterias Biotherapeutics to Report Third Quarter 2018 Results on Novem...
Asterias Biotherapeutics to Report Third Quarter 2018 Results on November 12, 2018 FREMONT, Calif., Nov. 02, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release third quarter 2018 financial and operating results on Monday, November 12, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on November...
Asterias Biotherapeutics Announces Positive Outcome from Data Review f...
Asterias Biotherapeutics Announces Positive Outcome from Data Review from OPC1 Spinal Cord Injury Study Meeting with Food and Drug Administration Remains on Track for End of 2018 FREMONT, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced a positive outcome from an independent Data Review Panel’s review of the data generated by patients enrolled in ...
Asterias Biotherapeutics Announces Facilities and IP License Option Ag...
Asterias Biotherapeutics Announces Facilities and IP License Option Agreements Transactions Provide Additional Cash to Advance Clinical Programs and Process Development while Reducing Fixed Overhead FREMONT, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced it has entered into two new agreements with an affiliate of Novo Nordisk, a multinational pha...
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Ne...
FDA Accepts Asterias Biotherapeutics’ Request to Meet and Discuss Next Phase of Development for OPC1 Spinal Cord Injury Clinical Program FREMONT, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the Food and Drug Administration (FDA) has accepted its request to meet to discuss proposed next steps for the OPC1 clinical development program. The C...
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Cli...
Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury FREMONT, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of OPC1 in the treatment of severe cervical spinal cord inju...
Asterias Biotherapeutics Announces Positive Outcome from Second Safety...
Asterias Biotherapeutics Announces Positive Outcome from Second Safety Review Committee Meeting and Open Enrollment for VAC2 Clinical Trial in Non-Small Cell Lung Cancer (NSCLC) Two Sites in the UK Currently Enrolling Patients FREMONT, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical tr...
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regen...
Asterias Biotherapeutics’ CEO Michael Mulroy to Participate on Regenerative Medicine Therapies Panel at the B. Riley FBR Healthcare Conference FREMONT, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that Michael Mulroy, President and Chief Executive Officer, will participate in a panel discussion at the B. Riley FBR Healthcare Conference at 8:20am ...
Asterias Biotherapeutics Reports Second Quarter Financial Results and ...
Asterias Biotherapeutics Reports Second Quarter Financial Results and Recent Development Progress Company Progressing Neurology and Immunotherapy Clinical Programs Anticipates Achievement of Significant Execution Milestones in the Second Half of 2018 and Full Year 2019 to Advance the Development of its Platform Technologies Conference Call and Webcast Today, August 9, at 5:00 p.m. ET FREMONT, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological c...
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phas...
Asterias Provides 12 Month Cohort 3 and 4 Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury -Company to Request Formal Meeting with FDA Under RMAT Designation this Quarter to Discuss Next Phase of Development for OPC Program- FREMONT, Calif., July 31, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the Company’s ongo...
Asterias Biotherapeutics to Report Second Quarter 2018 Results on Augu...
Asterias Biotherapeutics to Report Second Quarter 2018 Results on August 9, 2018 FREMONT, Calif., July 26, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that it will release second quarter 2018 financial and operating results on Thursday, August 9, 2018 after the close of the U.S. financial markets. The Company will host a conference call and webcast on August 9, 2...
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a C...
Asterias Provides Six Month Data Readout for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury - Current Readout Includes New Six Month Data for Cohort 5 and Aggregate Trial Data - - Results Continue to Demonstrate Favorable Safety Profile, Potential for Durable Cell Engraftment at the Injury Site and Improved Motor Function - - 12 Month Top-Line Readout from the Entire SCiStar Study Expected in First Quarter of 2019 - FREMONT, Calif., July 17, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing ...
Asterias Biotherapeutics Announces New Exclusive License Agreement wit...
Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California for Stroke IP; Second Pre-Clinical Collaboration Initiated to Test the Efficacy of AST-OPC1 for the Treatment of Stroke AST-OPC1 has Demonstrated Positive Safety Profile and Promising Signs of Efficacy in a Phase 1/2a Trial for Severe Spinal Cord Injury FREMONT, Calif., July 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with...
Asterias Biotherapeutics Announces Positive Outcome from Safety Review...
Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC) FREMONT, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced that the Safety Review Committee (SRC) for the first clinical trial of AST-VAC2, held a scheduled meeting to review the ...
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Hum...
Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer FREMONT, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a biotechnology company dedicated to developing cellular immunotherapies to treat cancer and cell-based therapeutics to treat neurological conditions associated with demyelination, today announced enrollment and dosing of the first subject in the first-in-human Phase 1 clinical trial of AST-VAC2 in the United Kingdom. This initial clinical trial, whic...
Asterias Biotherapeutics Announces Independent Data Monitoring Committ...
Asterias Biotherapeutics Announces Independent Data Monitoring Committee Completes Last Intermediate Review of AST-OPC1 Clinical Trial in Acute Spinal Cord Injury - AST-OPC1 Safety Profile Continues To Be Favorable - FREMONT, Calif., June 05, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today announced that the independent Data Monitoring Committee (DMC) for the company’s SCiSta...
Ford Equity US Rating and Forecast Report
Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.